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After application of haptens on the skin, immature dendritic cells (DC), also named Langerhans cells (LC), migrate
to the draining lymph node to sensitize naı¨ve T-lymphocytes. Migration of DC involves many factors including the
Cys-Cys chemokine receptor, CCR7. We investigated the effects of two well-known haptens, dinitrochlorobenzene
(DNCB) and nickel (NiSO4), on the expression of CCR7 on human DC derived from CD34
þ progenitor cells. Both
haptens were able to induce CCR7 expression and DC migration in response to Cys-Cys chemokine ligand, CCL19.
Since interleukin (IL)-1b and tumor necrosis factor (TNF)-a have been shown to participate in LC migration during
contact hypersensitivity, we tested the effect of their neutralization on CCR7 expression. Neutralization of IL-1b
activity did not modify CCR7 expression in response to both haptens. CCR7 expression was strongly dependent on
TNF-a in the case of DNCB, however, neutralization of TNF-a only partially reduced CCR7 expression upon NiSO4
treatment. DNCB, NiSO4 and TNF-a activated p38 mitogen-activated protein kinases (MAPK) and c-jun N-terminal
kinase (JNK). Both p38 MAPK and JNK participated to TNF-a production induced by DNCB. Inhibition of both p38
MAPK and JNK affected significantly CCR7 expression upon nickel treatment whereas only inhibition of p38 MAPK
but not of JNK downregulated CCR7 in the case of TNF-a stimulation. These results suggest that MAPK are nec-
essary for haptens to induce CCR7 expression. NiSO4, however, activates directly CCR7 expression through p38
MAPK and JNK activation whereas DNCB needs TNF-a whose secretion is also regulated by p38 MAPK and JNK.
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Application of low-molecular-weight chemicals (haptens) on
the skin may result in allergic contact hypersensitivity
(Grabbe and Schwarz, 1998). In vivo painting of murine
skin with chemicals, such as FITC, provokes an influx of
epidermal dendritic cells (DC) in the draining lymph nodes
24 h after hapten application (Hill et al, 1990). These epi-
dermal DC also named Langerhans cells (LC) express major
histocompatibilty complex (MHC) class II molecules and
co-stimulatory molecules such as CD86 (Aiba and Katz,
1990; Kripke et al, 1990; Becker et al, 1992; Macatonia et al,
1995). In animal models, production of pro-inflammatory
cytokines such as interleukin (IL)-1 and tumor necrosis
factor (TNF)-a have been shown to play a major role in
DC activation and migration in contact hypersensitivity
(Cumberbatch and Kimber, 1992; Enk and Katz, 1992; Enk
et al, 1993).
DC form a sentinel network able to detect, capture and
process antigens such as invading bacteria, viruses, tissue
damage and haptens (De Smedt et al, 1996; Aiba et al,
1997; Hacker et al, 1998; Cella et al, 1999). In peripheral
tissues such as the skin, the DC can be found in contact
with keratinocytes in an immature state with a high capacity
for antigen uptake and processing but unable to stimulate T
cells (Cella et al, 1997; Hart, 1997; Banchereau and Stein-
man, 1998). Upon antigen capture, stimulation by microbial
products but also in response to inflammatory cytokines
(TNF-a, IL-1y) or T cell-derived signals such as CD40
ligand, the DC undergo a maturation process leading to the
upregulation of co-stimulatory molecules (CD86, CD80,
CD40), MHC class II molecules and the CD83 protein (Caux
et al, 1994).
Maturing DC acquire the ability to migrate to the T cell
areas of lymph nodes through expression of chemokines
and chemokine receptors. Upon maturation, DC express
a new Cys-Cys chemokine receptor, CCR7, enabling
them to migrate in response to gradients of chemokines
(Cys-Cys chemokine ligand, CCL21 and then CCL19) to
the T cell zone of the draining lymph node (Yanagihara et al,
1998; Gunn et al, 1999; Saeki et al, 1999). Expression
of CCR7 is particularly important, as CCR7-deficient
mice show an impaired migration of activated LC
into draining lymph nodes after skin painting with FITC
and consequently, lack any contact hypersensitivity (Forster
et al, 1999).
Abbreviations: CCL, Cys-Cys chemokine ligand; CCR, Cys-Cys
chemokine receptor; DC, dendritic cell; DNCB, 2,4-dinitrochloro-
benzene; GM-CSF, granulocyte-macrophage-colony stimulating
factor; HPC, hematopoietic progenitor cell; IL, interleukin; JNK,
c-jun N-terminal kinase; LC, Langerhans cell; LPS, lipopolysaccha-
ride; MAPK, mitogen-activated protein kinase; MCF, mean cell fluo-
rescence; TNF-a, tumor necrosis factor-a
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The establishment of in vitro models of DC offered the
possibility to demonstrate that haptens were able to directly
activate cultured human DC derived from peripheral blood
monocytes (Aiba et al, 1997; Degwert, 1997). Several stud-
ies confirmed these observations showing the upregulation
of maturation markers (CD83, CD80, CD86, CD40) on hu-
man DC derived from peripheral blood monocytes or from
CD34þ precursor cells upon stimulation by haptens (Cout-
ant et al, 1999; Rougier et al, 2000; Tuschl et al, 2000; Arrighi
et al, 2001; De Smedt et al, 2001). Recently, the expression
of ccr7 mRNA in human DC stimulated by haptens and the
migration of these cells in response to CCL19 has been
observed (Aiba et al, 2000).
Mitogen-activated protein kinases (MAPK) have been
described to play a major role in DC maturation induced by
lipopolysaccharide (LPS) through toll-like receptors (Re-
scigno et al, 1998; Ardeshna et al, 2000; Underhill and
Ozinsky, 2002) or by inflammatory cytokines through binding
to specific receptors (Dunne and O’Neill, 2003; Wajant et al,
2003). Haptens such as nickel (NiCl2 and NiSO4), 2,4-di-
nitrochlorobenzene (DNCB) and 2,4-dinitrofluorobenzene
(DNFB) induce the phosphorylation of p38 MAPK and
c-jun N-terminal kinase (JNK). Inhibition of p38 MAPK is
correlated with alteration in phenotypic indicators of mat-
uration such as CD86, HLA-DR or CD83 in DC derived from
monocytes stimulated with nickel or DNCB (Arrighi et al,
2001; Aiba et al, 2003).
To date, there is no report evaluating pathways leading to
CCR7 expression upon hapten activation. We investigated
the regulation of CCR7 expression on human DC obtained
from CD34þ precursor cells stimulated by two well-known
haptens, DNCB and nickel (NiSO4). Our results show that
both NiSO4 and DNCB are able to induce CCR7 expression
through activation of JNK and p38 MAPK. NiSO4, however,
can directly induced CCR7 whereas DNCB needs TNF-a
whose production is also regulated by p38 MAPK and JNK.
Results
Haptens induce phenotypic maturation of human
CD34þ -derived DC Immature DC were generated from
CD34þ hematopoietic progenitor cells (HPC) cultured in the
presence of granulocyte-macrophage-colony stimulating
factor (GM-CSF), TNF-a and Flt-3L for 7 d. As shown by
flow cytometry studies, a significant proportion of these
cells express the specific markers of LC: CD1a (70%), E-
cadherin (85%) and Langerin (57%) known to be associated
with the Birbeck granules (Fig 1 and Table I). At day 7, these
cells are in an immature state as shown by the low expres-
sion of CD83 (0.9% of positive cells, total mean cell fluo-
rescence [MCF]¼9.9) and of the co-stimulatory molecule
CD86 (total MCF¼ 12.0). When DC are treated with either
500 mM of NiSO4 or 25 mM of DNCB for 24 h extensive
phenotypic changes occur with the upregulation of HLA-
DR, CD86 and CD83 and the downregulation of CD1a, E-
cadherin and Langerin. Viability of the cells after hapten
treatment was not inferior to 80% as assessed by trypan
blue exclusion (data not shown). In comparison, TNF-a
induces similar changes on CD86 and CD83 but not on
CD1a, E-cadherin and Langerin, which are not downregu-
lated by TNF-a treatment. These observations suggest that
NiSO4 and DNCB induce the maturation of human CD34
þ -
derived DC.
Human CD34þ -derived DC activated by haptens ex-
press CCR7 and respond to CCL19 To examine if haptens
can trigger the migration of DC from epidermis to lymph
nodes, we investigated the expression of the chemokine
receptor CCR7 by flow cytometry. Following 24 h of hapten
stimulation, CCR7 expression is induced only on CD83þ
cells (and on CD86þ cells, data not shown) (Fig 2), con-
firming a correlation between DC maturation and CCR7 ex-
pression during hapten stimulation. Moreover, kinetic stud-
ies indicate an earlier expression of CD83 compared with
CCR7 (data not shown). Using a Transwell system, we show
that CCR7 expression on hapten stimulated-DC lead to a
specific chemotactic response with the CCR7 chemokine
ligand, CCL19 (Fig 3). A random migration of non-treated
DC is detectable in the presence and in the absence of
CCL19. This non-chemotactic migration is abrogated by
haptens treatment and only 1% of cells treated 24 h
with NiSO4 migrate spontaneously compared with 14% of
Figure1
Flow cytometric analysis of immature and hapten-stimulated hu-
man dendritic cells. DC were generated by culturing CD34þ HPC
from cord blood in the presence of GM-CSF, TNF-a and Flt-3L for 7 d.
Cells were then washed and stimulated or not (control) by NiSO4 (500
mM), DNCB (25 mM) or TNF-a (500 U per mL) according to Materials and
Methods section for 24 h before being analyzed by flow cytometry.
The percentage expressing various cell surface antigens along with
total MCF are shown in Table I. Results of a representative experiment
out of 5.
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control cells. When DC are treated by haptens, however, DC
migration is significantly augmented in the presence of
CCL19 (14% vs 1% for NiSO4 and 7% vs 2% for DNCB).
The migration of NiSO4-treated cells is higher than the one
observed for DNCB-treated cells and correlates with the
results found for CCR7 expression (20%–45% CCR7þ cells
for NiSO4 vs 6%–15% for DNCB according to donors).
Taken together, these results suggest that the haptens
DNCB and NiSO4 are able to induce the expression of a
functional CCR7 protein on human CD34þ -derived DC.
Haptens increase ccr7 mRNA expression in DC To un-
derstand the mechanism of CCR7 induction by haptens, we
studied the kinetics of ccr7 mRNA expression in DC after
stimulation by haptens. ccr7 mRNA expression was evalu-
ated by semi-quantitative RT-PCR. ccr7 mRNA is present
4 h after hapten addition and increases in a time-dependent
manner (Fig 4). These observations suggest that stimulation
by haptens induces ccr7 expression at the transcriptional
level.
IL-1b synthesis from DC does not play a role in the ex-
pression of CCR7 induced by haptens In vivo studies
conducted in mice and using contact allergen suggested
that IL-1b and TNF-a played a role in the migration of LC. To
address the potential role of IL-1b released by DC in the
mechanism of hapten-induced CCR7 expression we used
the antagonist cytokine IL-1Ra. DC were pre-incubated with
1 mg per mL of IL-1Ra for 30 min before stimulation by
haptens. As shown on Fig 5, expression of CCR7 induced
by IL-1b is inhibited by IL-1Ra. IL-1Ra has no effect on the
expression of CCR7 on DC stimulated by haptens and also
Table I. Expression of markers on immature and hapten-stimulated human dendritic cells
Cell surface marker
Day 7
Day 7þ 24 h
Control NiSO4 DNCB TNF-a
% of pos-
itive cells MCF
% of pos-
itive cells MCF
% of pos-
itive cells MCF
% of pos-
itive cells MCF
% of pos-
itive cells MCF
Isotypic control Ab-FITC 2.7 2.0 1.1 2.9 1.3 2.5 1.8 2.9 5.9 3.0
CD1a 67.9 9.8 74.7 13.5 43.3 7.7 49.1 7.8 85.6 25.8
HLA-DR 97.2 56.3 98.8 114.9 99.1 237.0 99.8 255.7 92.8 45.0
Langerin 57.0 5.8 61.5 10.4 9.3 3.8 35.1 6.1 63.9 8.7
E-cadherin 84.6 14.1 78.3 21.6 51.4 7.7 65.8 11.1 91.8 25.5
CD86 84.2 12.0 75.1 12.8 83.0 82.2 78.9 22.3 77.7 17.0
Isotypic control Ab-PE 3.3 2.0 1.7 2.9 0.3 2.5 2.0 2.9 1.1 3.6
CD83 0.9 9.9 5.0 80.0 56.9 150.2 37.7 9.4 33.8 12.0
The results present in this table are the values of the cytometry study shown in Fig 1. The percentage of positive cells according to control Ab and total
mean fluorescence (MCF) are shown for the expression of each surface molecule.
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Figure 2
DC stimulated by haptens express both CD83 and CCR7. DC were generated by culturing CD34þ HPC from cord blood in the presence of GM-
CSF, TNF-a and Flt-3L for 7 d. Cells were then washed and stimulated or not (control) by NiSO4 (500 mM) or DNCB (25 mM) according to Materials
and Methods section for 24 h before being analyzed by flow cytometry. Two-dimensional plots show the surface expression profile of DC for CD83
and CCR7 or for control Abs. Quadrant position was determined using control Abs for each condition of stimulation. Numbers in each quadrant
represent cell percentages. Results of a representative experiment out of 5.
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on the expression of CD83 and CD86 (data not shown).
These data suggest that hapten-induced CCR7 expression
is independent from IL-1b release by DC.
Inhibition of TNF-a downregulates the expression of
CCR7 induced by haptens To study the role of TNF-a, also
described to play a major role in the migration of LC during
hypersensitivity reactions, we examined the effect of TNF-a
neutralization on the expression of CCR7 induced by hap-
tens. Cells were pre-incubated with an anti-TNF-a or with a
control Ab at 2 mg per mL before treatment with haptens. As
shown on Fig 6a, CCR7 and CD83 expressions induced by
DNCB are strongly inhibited by the anti-TNF-a Ab (80% and
60% reduction for CCR7 and CD83, respectively). In con-
trast, TNF-a neutralization has a weaker effect on CCR7 and
CD83 expressions induced by NiSO4 compared with DNCB
(35% and 40% reduction for CCR7 and CD83, respectively).
We next investigated the effect of anti-TNF-a on the induc-
tion of ccr7 mRNA by haptens. Following 6 h of stimulation,
ccr7 mRNA induced by DNCB is significantly reduced by
treatment with the anti-TNF-a (Fig 6b) whereas ccr7 mRNA
expression in NiSO4-stimulated DC is not affected for up to
24 h (Fig 6c).
These data suggest an essential role for TNF-a in CCR7
expression on DC stimulated by DNCB. On the other hand,
TNF-a seems not to be indispensable for CCR7 expression
induced by NiSO4 treatment.
p38 MAPK and JNK are activated by NiSO4, DNCB and
TNF-a In DC, haptens and TNF-a are also known to acti-
vate ‘‘stress pathways’’ such as p38 MAPK and JNK. These
reasons prompted us to analyze the activation of these
signalling pathways after NiSO4, DNCB or TNF-a stimula-
tion of DC. Our results show that NiSO4, DNCB and TNF-a
induce phosphorylation of p38 MAPK and JNK (Fig 7a, b).
Activation of these two MAPK by haptens shows compa-
rable kinetics with phosphorylation detectable at 15 min
and reaching a maximum at 1 h. The activation of p38
MAPK and JNK by TNF-a is present at 5 min of stimulation,
reaches a maximum after 15 min and then decreases.
MAPK activation by haptens was not due to TNF-a pro-
duction since anti-TNF-a treatment did not downregulate
p38 MAPK and JNK phosphorylation (data not shown).
TNF-a production induced by DNCB is dependent on
p38 MAPK and JNK activation Results showed above
suggest that the expression of CCR7 and CD83 induced by
DNCB was indirectly due to TNF-a production by DC. To
address this question, we quantified by ELISA the produc-
tion of TNF-a secreted by DC after 6 h of DNCB stimulation.
As shown in Fig 8, large amounts of TNF-a were produced.
Using well-described pharmacological inhibitors of p38
MAPK (SB203580) and JNK (SP600125) (Cuenda et al,
1995; Bennett et al, 2001) we were able to show that pre-
treatment with SB203580 completely abolishes the secre-
tion of TNF-a and that the inhibition of JNK downregulates
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Figure 3
Migration of hapten-stimulated DC in response to CCL19. DC were
generated by culturing CD34þ HPC from cord blood in the presence of
GM-CSF, TNF-a and Flt-3L for 7 d. Cells were then washed and stim-
ulated or not (control) by NiSO4 (500 mM) or DNCB (25 mM) according to
Materials and Methods section for 24 h. Migration assays were per-
formed in Transwell using medium alone or medium supplemented with
107M CCL19 (bottom well). Cells were placed in the top well
(2  105cells per well). Cells that had migrated to the underside of
the filter were counted microscopically. Experiments were performed in
quadruplicate and results were expressed as the mean  SD of mi-
grating cells. Results of a representative experiment out of 3.
po0.001 compared with migrating cells in absence of CCL19.
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Figure 4
Regulation of ccr7 mRNA expression by haptens in human DC. DC
were generated by culturing CD34þ HPC from cord blood in the pres-
ence of GM-CSF, TNF-a and Flt-3L for 7 d. Cells were then washed and
stimulated or not (control; C) by NiSO4 (500 mM) or DNCB (25 mM)
according to Materials and Methods section for 4, 7 or 24 h; t0 is the
starting time of the experiment. At the indicated time points, the ex-
pression of ccr7 mRNA was assessed by semi-quantitative RT-PCR. b-
actin was used as an internal mRNA control. Results of a representative
experiment out of 3.
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Figure5
Effect of IL-1Ra on the expression of CCR7 on DC stimulated by IL-
1b, NiSO4 or DNCB. DC were generated by culturing CD34
þ HPC from
cord blood in the presence of GM-CSF, TNF-a and Flt-3L for 7 d. Cells
were then washed and pre-treated with the antagonist of IL-1 receptor,
IL-1Ra (1 mg per mL) for 30 min before stimulation by IL-1b (10 ng per
mL), NiSO4 (500 mM) or DNCB (25 mM) according to Materials and
Methods section for 24 h. Cells were analyzed by flow cytometry for the
expression of CCR7. Results of a representative experiment out of 2.
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significantly but not completely TNF-a production induced
by DNCB (Fig 8). Secretion of TNF-a by NiSO4-stimulated
DC was also inhibited by SB203580 and SP600125 (data
not shown).
These results show that DNCB through the activation of
p38 MAPK and JNK induces the secretion of TNF-a, which
is indispensable for the expression of CCR7 induced by
DNCB on DC.
Effect of inhibition of p38 MAPK and JNK on the
expression of CCR7 induced by NiSO4 and TNF-a TNF-a
seems to play an essential role in the expression of CCR7
induced by DNCB; however, nickel may also regulate CCR7
expression but independently of TNF-a. Since NiSO4 and
TNF-a induce the activation of p38 MAPK and JNK we
evaluated the role of these MAPK on the expression of
CCR7 induced by NiSO4 and TNF-a.
As shown in Fig 9a, expressions of CD83/CCR7 induced
by NiSO4 and TNF-a are nearly completely abrogated upon
inhibition of p38 MAPK activity. In addition, SB203580 in-
hibits ccr7 mRNA expression upon NiSO4 stimulation (data
not shown). These results indicate an essential role for p38
MAPK in CCR7 expression induced by NiSO4 and TNF-a.
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Figure 6
Effects of anti-TNF-a antibody on CD83 and CCR7 expression in-
duced by haptens. DC were generated by culturing CD34þ HPC from
cord blood in the presence of GM-CSF, TNF-a and Flt-3L for 7 d. Cells
were then washed and pre-treated with anti-TNF-a (2 mg per mL) or
mouse IgG1 (control antibody) for 30 min and then treated or not
(control) by TNF-a (500 U per mL), NiSO4 (500 mM) or DNCB (25 mM)
according to Materials and Methods section. (a) Cells were analyzed 24
h after stimulation by flow cytometry for the expression of CD83/CCR7.
Quadrant position was determined using control Abs for each condition
of stimulation. Numbers in each quadrant represent cell percentages.
Results of a representative experiment out of 3. (b) After 6 h of stim-
ulation the expression of ccr7 mRNA was assessed by semi-quanti-
tative RT-PCR. b-actin was used as an internal mRNA control. Fold
represents the ratio of ccr7/b-actin of treated cells compared with
control cells at the same time of stimulation. Results of a representative
experiment out of 3. (c) After 6 and 24 h of stimulation by TNF-a or
NiSO4 the expression of ccr7 mRNA was assessed by semi-quantita-
tive RT-PCR. Fold represents the ratio of ccr7/b-actin of treated cells
compared with control cells at the same time of stimulation. Results of
a representative experiment out of 3.
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Figure7
Kinetic of activation of p38 MAPK and JNK induced by NiSO4,
DNCB and TNF-a. DC were generated by culturing CD34þ HPC from
cord blood in the presence of GM-CSF, TNF-a and Flt-3L for 7 d. (a)
Cells were stimulated or not (control; C) with NiSO4 (500 mM), DNCB (25
mM) or TNF-a (500 U per mL) and then lysed at different time of stim-
ulation. The level of phosphorylation of p38 MAPK was evaluated by
western blotting using an Ab raised against phosphorylated forms of
p38 MAPK. Membrane was then probed again with an anti-p38 MAPK
Ab for loading control. Blots are representative of results obtained in 3
independent experiments. (b) Cells were stimulated or not (control; C)
with NiSO4 (500 mM), DNCB (25 mM) or TNF-a (500 U per mL) and then
lysed at different time of stimulation. The level of phosphorylation of
JNK1/2 was evaluated by western blotting using an Ab raised against
phosphorylated forms of JNK. Blot show the p54 and the p46 forms of
JNK1/2. Membrane was then probed again with an anti-p38 MAPK Ab
for loading control. Blots are representative of results obtained in 3
independent experiments.
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Figure8
Effects of inhibitors of p38 MAPK (SB203580) and JNK1/2
(SP600125) on TNF-a secretion induced by DNCB. DC were gener-
ated by culturing CD34þ HPC from cord blood in the presence of GM-
CSF, TNF-a and Flt-3L for 7 d. Cells were then washed and pre-treated
by DMSO (0.05%), SB203580 (20 mM) or SP600125 (20 mM) for 30 min
and further stimulated or not (control) with DNCB (25 mM) as described
in the Materials and Methods section for 6 h. After culture, the su-
pernatants were recovered and examined for TNF-a secretion by an
ELISA. Experiments were performed in triplicate and results were ex-
pressed as the mean  SEM (n¼3). Results of a representative ex-
periment out of 2. po0.001.
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We then investigated the role of JNK pathway on the
mechanism of CCR7 expression. Upon TNF-a stimulation,
expression of CCR7 is not abrogated by inhibition of JNK
activity (Fig 9b). In contrast, SP600125 seems rather to
augment the expression of CD83 upon TNF-a stimulation
(49% in the presence of SP600125 vs 36%). Pre-treatment
of DC with SP600125 before NiSO4 stimulation strongly
decreases CD83 and CCR7 expression. These results show
that the JNK pathway is necessary for CCR7 expression
upon NiSO4 stimulation but is not involved upon stimulation
by TNF-a.
Discussion
Contact sensitizers have been shown to induce DC matu-
ration in vitro (Aiba et al, 1997; Degwert et al, 1997; Rougier
et al, 1998; Coutant et al, 1999; Arrighi et al, 2001; De
Smedt et al, 2001). According to the crucial role of LC mi-
gration from epidermis to lymph nodes in the initiation
phase of contact hypersensitivity, we explored the mech-
anism of CCR7 expression after hapten-stimulation of
human DC derived from CD34þ hematopoietic precursors.
Our results show that the two haptens, DNCB and NiSO4,
induce the expression of the ccr7 gene and DC migration in
response to CCL19, a ligand of CCR7. This work also sug-
gests the essential role of TNF-a in CCR7 expression
induced by DNCB whereas, TNF-a participates only par-
tially in CCR7 expression due to NiSO4 stimulation. p38
MAPK and JNK are activated upon addition of NiSO4,
DNCB or TNF-a and participate to the secretion of TNF-a
induced by DNCB and NiSO4. In addition, p38 MAPK and
JNK are involved in CCR7 regulation induced by NiSO4
whereas only p38 MAPK plays a role upon TNF-a addition.
The initiation of contact hypersensitivity is occurring in
the skin through the activation of LC by haptens. There are
two ways to obtain human LC in vitro. When DC are gen-
erated from monocytes using GM-CSF and IL-4, addition of
TGF-b has been shown to induce the differentiation of
peripheral blood monocytes in LC (Geissmann et al, 1998).
In the presence of GM-CSF and TNF-a, CD34þ progenitor
cells lead to a population of DC with the characteristics of
LC (Caux et al, 1992). After 7 d of culture of CD34þ cells in
the presence of GM-CSF, TNF-a and Flt-3L, we obtained a
population of cells expressing specific attributes of LC such
as CD1a, Langerin and E-cadherin. The stimulation of these
cells with DNCB or NiSO4 induces the upregulation of
CD83, CD86 and HLA-DR, but also the downregulation
of CD1a, Langerin and E-cadherin. Nickel was also more
efficient in the induction of CD83 and CD86 than DNCB.
Following their activation, DC have to migrate to lymph
nodes where antigen presentation to naı¨ve T cells takes
place. Immature DC upon induction of maturation after
stimulation by bacterial products or inflammatory cytokines
upregulate CCR7, a chemokine receptor that drives their
migration to the lymphatics (Yanagihara et al, 1998; Gunn
et al, 1999; Saeki et al, 1999). The migration of DC through
CCR7 has been also observed after hapten stimulation
(Aiba et al, 2000). Our results show that hapten stimulation
provokes the appearance of a CCR7þ /CD83þ cell popu-
lation that migrates in response to CCL19, one of the two
existing CCR7 ligands with CCL21. Surprisingly, a signifi-
cant number of non-treated DC not expressing CCR7
migrate spontaneously. In keeping with results obtained
after LPS addition (data not shown) and works by others,
we believe that their migration is a random migration and
not a chemotactic response (Aiba et al, 2000). We also ob-
serve a strong decrease of this spontaneous migration upon
hapten treatment without CCL19 addition. We do not have
an explanation for this observation that has also been
recorded by others on human DC obtained from monocytes
(Aiba et al, 2000).
Several groups recently showed, using human mon-
ocyte-derived DC cultured in presence or absence of
serum, that signals provided by prostaglandin-E2 (PGE2)
were required for migration of mature DC in response to
CCL19 and CCL21 (Luft et al, 2002; Scandella et al, 2002).
In our study, we observe an efficient migration of DC stim-
ulated by LPS (data not shown) or by haptens without ad-
dition of lipid mediators as also observed by others using
different models of DC (Aiba et al, 2000; Luft et al, 2002).
According to several in vivo studies conducted in murine
models, production of pro-inflammatory cytokines, such as
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Figure 9
Effects of inhibitors of p38 MAPK (SB203580) and JNK1/2
(SP600125) on CD83/CCR7 expression. DC were generated by cul-
turing CD34þ HPC from cord blood in the presence of GM-CSF, TNF-a
and Flt-3L for 7 d. Cells were then washed and pre-treated by
SB203580 (20 mM) (a) or SP600125 (20 mM) (b) for 30 min and further
stimulated or not (control) with NiSO4 (500 mM) or TNF-a (500 U per
mL). Cells were analyzed 24 h after stimulation by flow cytometry for
the expression of CD83/CCR7. Quadrant position was determined us-
ing control Abs for each condition of stimulation. Numbers in each
quadrant represent cell percentages. Results of a representative ex-
periment out of 3.
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IL-1 and TNF-a, have been shown to play a major role in DC
activation and migration (Cumberbatch and Kimber, 1992,
1995; Enk and Katz, 1992; Enk et al, 1993; Cumberbatch
et al, 1997). In vivo, these cytokines can be produced by
the keratinocytes and DC themselves also secrete large
amounts of inflammatory cytokines as well as chemokines
(Wang et al, 1999). This autocrine loop of mediators’ pro-
duction may contribute to activation and maturation of DC.
Our results suggest that after hapten stimulation, IL-1b does
not participate in DC migration through the induction of
CCR7. In contrast, TNF-a produced through the activation
of p38 MAPK and JNK is necessary for CCR7 expression
induced by DNCB and neutralization of TNF-a strongly
downregulates ccr7 mRNA expression. Neutralization of
TNF-a, however, only affects partially the expression of
CCR7 and does not modify ccr7 mRNA expression after
NiSO4 addition. These results suggest that IL-1b and TNF-a
are not essential for CCR7 expression induced by NiSO4
and that haptens may not use the same pathways to
upregulate CCR7.
Few studies so far have described signal transduction
pathways leading to CCR7 expression. PGE2 through
cAMP signalling upregulated CCR7 expression on human
monocyte-derived DC (Scandella et al, 2002). TREM-2/
DAP12 promoted the expression of CCR7 on human DC
derived from monocytes through ERK but independently of
p38 MAPK and NF-kB. In the same model, however, LPS
upregulated CCR7 through activation of p38 MAPK and
NF-kB, but not ERK (Bouchon et al, 2001). In murine
thymocytes, Raf-1 and Ca2þ -dependent signals have been
shown to be essential to induce CCR7 expression (Adachi
et al, 2001).
The JNK and p38 MAPK cascades are referred as stress-
activated MAPK pathways because they are strongly acti-
vated by stress-inducing agonists such as LPS, inflamma-
tory cytokines or xenobiotics. The availability of drugs such
as SB203580, SP600125 inhibiting p38 MAPK and JNK,
respectively, has allowed great progress in this field keeping
in mind that they are not totally specific for the target they
have been designed (Bennett et al, 2001). Both p38 MAPK
and JNK are rapidly phosphorylated in our model upon
hapten stimulation and are involved in TNF-a secretion. In-
hibition of p38 MAPK is detrimental for CCR7 expression
after addition of either NiSO4 or TNF-a. JNK, however, is
only necessary after addition of NiSO4 but not of TNF-a.
This is the first observation that JNK may play a role in DC
maturation after hapten stimulation. Upon NiSO4 addi-
tion CD83 expression is also affected after addition of
SB203580 or SP600125 showing similarities with the reg-
ulation of CCR7 expression. Recently, it has been shown
that SP600125 inhibited the expression of IL-12 p70 in-
duced by LPS and flagellin in DC derived from monocytes
(Agrawal et al, 2003).
In conclusion, this work suggests that haptens induce
CCR7 expression on DC derived from CD34þ precursors
leading to the migration of these cells in response to CCL19.
Moreover, this study indicates that DNCB induces CCR7
expression through a MAPK-dependent production of TNF-
a On the other hand, nickel upregulates CCR7 independ-
ently from TNF-a but also through a MAPK-dependent
pathway.
Materials and Methods
Generation of DC from human cord blood CD34þ hematopoie-
tic progenitor cells Umbilical cord blood samples were obtained
after full-termed delivery from women who were clearly informed
about the aim of the study and gave their informed consent.
Mononuclear cells were prepared by density centrifugation using
Medium for Lymphocyte Isolation (Eurobio, Les Ulis, France). Cells
bearing the CD34þ antigen were isolated from the mononuclear
fraction through magnetic positive selection using MiniMACS sep-
aration columns (Miltenyi Biotec, Bergisch Gladbach, Germany)
and anti-CD34þ antibodies coated on magnetic beads (Direct
CD34 progenitor cell isolation kits, Miltenyi Biotec). After purifica-
tion the isolated cells were 80%–95% CD34þ cells.
Cultures were established in the presence of GM-CSF 200 U
per mL (Leucomax 400 a kind gift of Novartis & Schering-Plough,
Rueil-Malmaison, France), rhTNF-a 50 U per mL (kindly provided
by Dr Schmidt, Mainz, Germany) and Flt-3 Ligand (Flt-3L) 50 ng per
mL (PeproTech, Tebu, Le Perray-en-Yvelines, France) in RPMI 1640
containing Glutamax I supplemented with 10% heat-inactivated
fetal calf serum, 1 mM sodium Pyruvate, 1% penicillin and strep-
tomycin antibiotic solution (all from Gibco Invitrogen, Paisley, UK).
Cells were then incubated at 3  105 cells per mL at 371C in a 5%
CO2, 95% air atmosphere. On day 7, depending on the donor,
between 65% and 85% of the cells were CD1aþ .
Chemical treatment of immature DC On day 7, DC were washed
three times before treatment with either NiSO4 (500 mM, Sigma,
St Louis, MO), IL-1b (10 ng per mL, R&D systems, Abingdon, UK)
or TNF-a (500 U per mL) for different period of time. In the case of
DNCB (25 mM dissolved in DMSO at final concentration of 0.05%,
Sigma) treatment was performed for only 30 min and cells were
then washed three times and re-incubated for different period of
time. Because cells stimulated by DMSO 0.05% for DNCB control
showed always the same characteristics than unstimulated cells,
their data are not shown on the figures (data not shown).
In some experiments, DC were pre-treated for 30 min by either
anti-TNF-a (2 mg per mL, R&D systems), control isotype-matched
antibody (2 mg per mL, produced in the laboratory), IL-1Ra (1 mg
per mL, the IL-1Ra mutant DoB0039 was kindly provided by
Dr Boraschi (Ruggiero et al, 1997)), SB203580 (20 mM dissolved
in DMSO, Calbiochem EMD Biosciences, Darmstadt, Germany),
SP600125 (20 mM dissolved in DMSO, Calbiochem) or DMSO
0.05% used for vehicle control of the inhibitors.
Flow cytometry analysis Cultured DC were re-suspended at
2.5  105 cells in 30 mL of culture medium and incubated for 30
min at 41C with monoclonal antibodies (mAbs) or appropriate iso-
typic controls. After three washes in cold phosphate-buffered sa-
line (PBS) supplemented with 0.5% of BSA, cells were fixed with
1% paraformaldheyde in PBS. The following mAbs were used:
anti-CD1a (BL6, Immunotech, Marseille, France), anti-HLA-DR
(L243, BD Biosciences, Erembodegem, Belgium), anti-E-cadherin
(HECD-1, R&D systems), anti-Langerin (DCGM4, Immunotech),
anti-CD86 (2331, BD Biosciences), anti-CCR7 (2H4, BD Biosci-
ences) and PE-conjugated anti-CD83 (HB15a, Immunotech).
A second step including a goat anti-mouse IgG-FITC (0819,
Immunotech) was added for anti-CD1a, anti-HLA-DR, anti-E-cad-
herin, anti-Langerin and anti-CD86. In the case of anti-CCR7, a
goat anti-mouse IgM (Alexa Fluor 633, Molecular Probes, Leiden,
The Netherlands) was used for the second step. Appropriate iso-
types controls were used at the same concentration as the test
antibody to determinate the positive cells. Cells were analyzed on a
FACSCalibur cell analyzer (Becton Dickinson) using CellQuest
software (Becton Dickinson). Cellular debris were eliminated from
the analysis using a gate on forward and side scatter. For each
sample 104 cells were analyzed.
RT-PCR analysis Total RNA was extracted after lysis of cells in
TRIzol Reagent (Invitrogen) by the guanidium thiocyanate method
as mentioned by the manufacturer. RNA was quantified by spec-
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trophotometry. First strand cDNA was synthesized from total RNA
extracted in RNAse-free conditions. The reaction was performed
on 2 mg of total RNA with an oligo dT primer (MWG Biotech,
Ebersberg, Germany) and 2 U of AMV RT (Promega, San Luis
Obispo, CA). PCR reaction was performed using 1 U of Taq Pol-
ymerase (QBiogen, Montre´al, Canada) and 30 cycles (941C for 1
min, 551C for 2 min and 721C for 3 min). Specific ccr7 primers were
previously described by Dieu et al (1998): 50-GATTACATCGGA
GACAACACC-30 forward primer and 50-TAGTCCAGGCAGAAG-
AGTCG-30 reverse primer were used in PCR reaction mixture. PCR
products were visualized at 1067 bp on 1% agarose gel containing
ethidium bromide. b-actin was used to control and calibrate cDNA
synthesis. Specific b-actin primers 50-GGGTCAGAAGGATTCC-
TATG-30 for the forward primer and 50-GGTCTCAAACAT-
GATCTGGG-30 for the reverse primer were used in PCR reaction
mixture (23 cycles; 951C 30 s, 551C 1 min and 721C 1 min). The
folds indicated the ratio of ccr7/b-actin of treated cells compared
with control cells at the same time of stimulation.
Chemotaxis assay Cell migration was evaluated using a chemo-
taxis microchamber technique (5 mm-pore diameter 24-wells Tran-
swell polycarbonate membrane, Costar, Acton, MA). After three
washes cells were re-suspended at 2  105 cells per 100 mL and
placed into the upper chamber. Culture medium (600 mL) with or
without recombinant human CCL19 (107M) (R&D Systems) was
introduced in the lower chamber. Cells were then incubated for 90
min at 371C in a 5% CO2, 95% air atmosphere). After removal of
the Transwell inserts, migrated cells were re-suspended in 100 mL
and counted microscopically.
Western blot analysis Immature DC (2  106 cells per 2 mL) were
exposed to NiSO4 (500 mM), DNCB (25 mM) or TNF-a (500 U per
mL) for the indicated periods of time. Cells were washed in cold
PBS before lysis in 50 mL of lysis buffer (20 mM Tris pH 7.4, 137
mM NaCl, 2 mM EDTA pH 7.4, 1% Triton, 25 mM b-glycerophos-
phate, 1 mM Na3VO4, 2 mM sodium pyrophosphate, 10% glycerol,
1 mM PMSF, 10 mg per mL aprotinin and 10 mg per mL leupeptin).
The homogenates were centrifuged at 17,000 g for 20 min at 41C.
Equal amounts of denatured proteins were loaded onto 12.5%
SDS-PAGE gel and transferred on PVDF membrane (Amersham
Biosciences, Les Ulis, France). Membranes were then incubated
with Abs raised against the phosphorylated forms of p38 MAPK
and JNK1/2 (all from Cell Signaling Technology, Ozyme, St Quentin
en Yvelines, France). Immunoreactive bands were detected by
chemiluminescence (ECL solution, Amersham Biosciences). Strip-
ping of membranes was performed to analyze total p38 MAPK
expression as a loading control with an Ab raised against total p38
MAPK (p38 N20, Santa Cruz Biotechnology, Santa Cruz, California).
Enzyme-linked immunosorbant assay for TNF-a produc-
tion Immature DC were pre-treated 30 min with MAPK inhibitors
or with DMSO (0.05%) and then stimulated by DNCB or DMSO
(0.05%) for 30 min. Cells were then washed three times and
re-incubated with addition of inhibitors in the culture medium. The
culture supernatants of DC were recovered 6 h after culture. TNF-a
production was measured by ELISA kit obtained from Becton
Dickinson (Human TNF-a BD OptEIA ELISA set) using 96-well
microtiter plates according to the manufacturer’s instructions.
Statistical analysis Dunett’s multicomparison modification of
Student’s t test was used to asses the statistical significance of
experimental data for continuous variables. Experimental data
were considered statistically different from control at po0.05.
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